DIAMOND BIOFUND INC (6901) - Net Assets
Based on the latest financial reports, DIAMOND BIOFUND INC (6901) has net assets worth NT$9.23 Billion TWD (≈ $290.68 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$9.39 Billion ≈ $295.99 Million USD) and total liabilities (NT$168.32 Million ≈ $5.30 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check DIAMOND BIOFUND INC (6901) asset resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$9.23 Billion |
| % of Total Assets | 98.21% |
| Annual Growth Rate | 28.06% |
| 5-Year Change | 13.99% |
| 10-Year Change | N/A |
| Growth Volatility | 80.16 |
DIAMOND BIOFUND INC - Net Assets Trend (2019–2024)
This chart illustrates how DIAMOND BIOFUND INC's net assets have evolved over time, based on quarterly financial data. Also explore DIAMOND BIOFUND INC total assets for the complete picture of this company's asset base.
Annual Net Assets for DIAMOND BIOFUND INC (2019–2024)
The table below shows the annual net assets of DIAMOND BIOFUND INC from 2019 to 2024. For live valuation and market cap data, see 6901 company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$10.37 Billion ≈ $326.81 Million |
-19.35% |
| 2023-12-31 | NT$12.86 Billion ≈ $405.22 Million |
+16.39% |
| 2022-12-31 | NT$11.05 Billion ≈ $348.15 Million |
+6.34% |
| 2021-12-31 | NT$10.39 Billion ≈ $327.41 Million |
+14.20% |
| 2020-12-31 | NT$9.10 Billion ≈ $286.71 Million |
+202.26% |
| 2019-12-31 | NT$3.01 Billion ≈ $94.85 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to DIAMOND BIOFUND INC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100897400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$8.51 Billion | 82.08% |
| Other Components | NT$4.38 Billion | 42.20% |
| Total Equity | NT$10.37 Billion | 100.00% |
DIAMOND BIOFUND INC Competitors by Market Cap
The table below lists competitors of DIAMOND BIOFUND INC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tonnellerie Francois Freres SA
PA:TFF
|
$366.39 Million |
|
Hengxin Mobile Business
SHE:300081
|
$366.39 Million |
|
Singaraja Putra
JK:SINI
|
$366.40 Million |
|
Worldex Industry & Trading Co. Ltd
KQ:101160
|
$366.45 Million |
|
Gopal Snacks Ltd
NSE:GOPAL
|
$366.26 Million |
|
AQUILA PART PROD COM
RO:AQ
|
$366.14 Million |
|
Sichuan Huati Lighting Tech
SHG:603679
|
$366.10 Million |
|
Meter Instruments Co. Ltd
SHE:301006
|
$366.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in DIAMOND BIOFUND INC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 12,861,965,000 to 10,373,048,000, a change of -2,488,917,000 (-19.4%).
- Net loss of 2,518,040,000 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-2.52 Billion | -24.27% |
| Other Changes | NT$29.12 Million | +0.28% |
| Total Change | NT$- | -19.35% |
Book Value vs Market Value Analysis
This analysis compares DIAMOND BIOFUND INC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.12x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.06x to 1.12x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | NT$4.46 | NT$13.65 | x |
| 2020-12-31 | NT$9.11 | NT$13.65 | x |
| 2021-12-31 | NT$10.88 | NT$13.65 | x |
| 2022-12-31 | NT$14.29 | NT$13.65 | x |
| 2023-12-31 | NT$16.51 | NT$13.65 | x |
| 2024-12-31 | NT$12.20 | NT$13.65 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently DIAMOND BIOFUND INC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -24.27%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-24.27%) is below the historical average (7.48%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -12.32% | 0.00% | 0.00x | 1.02x | NT$-671.94 Million |
| 2020 | 66.92% | 0.00% | 0.00x | 1.02x | NT$5.18 Billion |
| 2021 | 27.44% | 0.00% | 0.00x | 1.02x | NT$1.81 Billion |
| 2022 | 7.22% | 0.00% | 0.00x | 1.01x | NT$-307.25 Million |
| 2023 | -20.09% | 0.00% | 0.00x | 1.01x | NT$-3.87 Billion |
| 2024 | -24.27% | 0.00% | 0.00x | 1.03x | NT$-3.56 Billion |
Industry Comparison
This section compares DIAMOND BIOFUND INC's net assets metrics with peer companies in the Asset Management industry.
No peer company data available for comparison.
About DIAMOND BIOFUND INC
Diamond Biofund Inc. is a venture capital firm specializing in evergreen funds. The firm seeks investment in start-ups and early ventures. It typically invests in biotechnology and medical investments, including new drug R&D, high-end medical equipment, innovative medical services and channels, and agricultural biotechnology. Diamond Biofund Inc. was founded in 2013 and is based in Taipei, Taiwan.